Glucagon-like peptide-1 (GLP-1)receptoragonistsare incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity.GLP-1receptorago...
Objectives To characterise patterns of use of glucagon-like peptide1receptoragonists(GLP-1RAs) and assess the associations between variousGLP-1RA treatment scenarios and theriskof major adversecardiovascularevents.Design Target trial emulation.Setting Electronic healthcare databases of US Department of Veterans Affairs,1January 2017 to 31 December 2023. Data obtained from domains in ...
Across the studies, patients takingGLP-1drugs had lower rates ofcardiovasculardeath, non-fatal heart attack, and non-fatal stroke, along with fewer hospitalizations for heart failure. Theriskreduction was consistent across different drugs and study designs, showing this isn't limited to a single medication.
Cardiovascularoutcome trials (CVOTs) in people living with type 2 diabetes mellitus and obesity have confirmed thecardiovascularbenefits of glucagon-like peptide1receptoragonists(GLP-1RAs), including reducedcardiovascularmortality, lower rates of myocardial infarction, and lower rates of stroke. Thecardiovascularbenefits observed followingGLP-1RA treatment could be secondary to ...
Glucagon-like peptide-1 (GLP-1)receptoragonistsnow serve as therapeutic agents forcardiovasculardiseases (CVDs) beyond their original use for treating type 2 diabetes mellitus (T2DM). This review combines molecular mechanisms with clinical evidence to demonstrate howGLP-1agonistshelp lowercardiovascularriskfor conditions, including atherosclerosis, heart failure, stroke, and ...
Furthermore, visual representations like the one above help us fully grasp the concept of Glp-1 Receptor Agonist And Cardiovascular Risk.
The review of 11 majorcardiovascularoutcome trials, published in the journalCardiovascularDiabetology - Endocrinology Reports showed treatment withGLP‑1receptoragonistsreduced therisk...
